Cardiff Oncology, Inc. (Nasdaq: CRDF), a US-based clinical-stage biotechnology company, announced on Tuesday that it has dosed its first subject with its investigational drug onvansertib in its Phase two ONSEMBLE trial (NCT05593328).
The trial is aimed at showcasing a clinically meaningful difference in response and onvansertib's contribution to standard of care (SoC) FOLFIRI/bevacizumab for the second line treatment of subjects with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).
The Phase 2 ONSEMBLE trial is conducted in subjects with mCRC who have a documented KRAS or NRAS mutation and have earlier received one prior chemotherapy regimen with or without bevacizumab in the first line metastatic setting. Subjects are being randomised to onvansertib and FOLFIRI/bevacizumab compared to FOLFIRI/bevacizumab (standard of care).
Heinz-Josef Lenz, MD, USC Norris Comprehensive Cancer Center, is heading the trial. He has experience with the firm's mCRC clinical program, having served as the principal investigator for the Phase 1b/2 trial.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886